Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | MTOR | P42345 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6647382 | 0.89 | MAPK14 (0.37) | SMN1; SMN2PIK3CAMTORRAB9ATP53 | |
| SCHEMBL6644980 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2RAB9ATP53MEN1GAA | |
| SCHEMBL6645513 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2PIK3CAMTORRAB9ATP53 | |
| SCHEMBL6645859 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2PIK3CAMTORRAB9ATP53 | |
| SCHEMBL6647756 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2RAB9ATP53MEN1KMT2A | |
| SCHEMBL6645415 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2RAB9ATP53MEN1GAA | |
| SCHEMBL6502051 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2PIK3CAMTORRAB9ATP53 | |
| SCHEMBL6501410 | 0.74 | SMN1; SMN2 (0.60) | SMN1; SMN2RAB9ATP53KMT2ANPC1 | |
| SCHEMBL6646524 | 0.74 | SMN1; SMN2 (0.56) | SMN1; SMN2RAB9ATP53MEN1GAA | |
| SCHEMBL6643427 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2RAB9ATP53MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | SMN1; SMN2 1836/4885PIK3CA 3819/4885MTOR 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.